Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL
At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial
ASCO 2026
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
News
ASCO 2026
Trending now
Multiple Myeloma
SOHO Insider Podcast
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously
ASCO 2026
Trending now
Meetings / Conferences
Multiple Myeloma
News
Dr. Hans Lee on MRNA-2808 in relapsed or refractory multiple myeloma
Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational
Lymphoma
Indolent B-Cell Lymphomas
Mantle Cell Lymphoma
News
FDA grants orphan drug designation to EO2463 to treat indolent non-Hodgkin lymphoma
The US Food and Drug Administration has granted Orphan Drug Designation to EO2463 immunotherapy for the treatment of patients with indolent non-Hodgkin lymphoma
AACR 2026
Cellular Therapy
Video Interviews
Tri-specifc CAR-T shows early activity in B-cell malignancies
The Phase 1 trial evaluates DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malignancies who have often failed prior CAR T-cell treatments.
Trending now
Community Oncology
Leukemia
Myelodysplastic Syndromes
Video Interviews
What are the barriers to research in the community oncology setting?
In this session from the SOHO Insider Community Oncology Brown Bag series, Luke Fletcher, MD, presents on an exploration of barriers and solutions
AACR 2026
Cellular Therapy
Multiple Myeloma
News
Video Interviews
Drs. Ghobrial and Nadeem discuss results from the phase II CAR-PRISM trial
The discussion also covers the study's safety profile and the potential for these early-stage immunotherapies to achieve long-term curative results.
Leukemia
Acute Myeloid Leukemia
News
FDA approves oral combo for newly diagnosed AML
The oral combination is used with venetoclax for patients who are at least 75 years old or have other medical conditions that prevent
AACR 2026
Cellular Therapy
Video Interviews
Dr. Roy Jensen discusses POC CAR-T manufacturing
In this SOHO Insider interview from the 2026 AACR Annual Meeting, Roy Jensen, MD, vice chancellor and director of the University of Kansas
Myeloproliferative Neoplasms
Polycythemia Vera
Primary Myelofibrosis
News
FDA approves ruxolitinib extended-release tablets for MF, PV, and GVHD
The US Food and Drug Administration (FDA) has approved ruxolitinib (Jakafi XR) extended-release tablets for adults with intermediate or high-risk myelofibrosis and adults